Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $144.38, for a total value of $28,876.00. Following the transaction, the executive vice president now owns 21,996 shares in the company, valued at approximately $3,175,782.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, July 17th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $154.97, for a total value of $30,994.00.
  • On Thursday, June 15th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $150.65, for a total value of $30,130.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down 0.94% on Thursday, hitting $146.01. The company’s stock had a trading volume of 285,344 shares. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The stock has a market cap of $8.77 billion, a PE ratio of 22.49 and a beta of 1.10. The firm has a 50 day moving average of $153.65 and a 200-day moving average of $147.43.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. The business had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.67 earnings per share. On average, analysts expect that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.

WARNING: This piece of content was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/17/jazz-pharmaceuticals-plc-jazz-evp-michael-patrick-miller-sells-200-shares.html.

Several research firms have recently weighed in on JAZZ. Cowen and Company reiterated an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Wells Fargo & Company reiterated an “outperform” rating and set a $177.00 price objective (down previously from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Piper Jaffray Companies reiterated a “buy” rating and set a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Janney Montgomery Scott reiterated a “buy” rating and set a $192.00 price objective (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $174.00 price objective on the stock in a report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $182.72.

Several hedge funds have recently modified their holdings of JAZZ. US Bancorp DE increased its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares during the last quarter. World Asset Management Inc acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Gargoyle Investment Advisor L.L.C. acquired a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $206,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $211,000. 87.22% of the stock is owned by institutional investors.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.